References
- [No authors listed]The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf200752759217508116
- LempMAReport of the National Eye Institute/Industry workshop on Clinical Trials in Dry EyesCLAO J19952142212328565190
- SchaumbergDASullivanDABuringJEDanaMRPrevalence of dry eye syndrome among US womenAm J Ophthalmol2003136231832612888056
- SchaumbergDADanaRBuringJESullivanDAPrevalence of dry eye disease among US men: estimates from the Physicians’ Health StudiesArch Ophthalmol2009127676376819506195
- [No authors listed]The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf2007529310717508117
- MiljanovićBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of lifeAm J Ophthalmol2007143340941517317388
- BehrensADoyleJJSternLDysfunctional Tear Syndrome Study GroupDysfunctional tear syndrome: a Delphi approach to treatment recommendationsCornea200625890090717102664
- LempMAEpidemiology and classification of dry eyeAdv Exp Med Biol19984387918039634969
- RaoSNTopical cyclosporine 0.05% for the prevention of dry eye disease progressionJ Ocul Pharmacol Ther201026215716420415623
- GaytonJLEtiology, prevalence, and treatment of dry eye diseaseClin Ophthalmol2009340541219688028
- RajpalRKDigbyDD’AversaGMahFHollanderDAConwayTIntraocular pressure elevations with loteprednol etabonate: a retrospective chart reviewJ Ocul Pharmacol Ther201127330530821574815
- [No authors listed]Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf20075216317817508120
- SallKStevensonODMundorfTKReisBLTwo multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study GroupOphthalmology2000107463163910768324
- RaoSNReversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawalJ Ocul Pharmacol Ther201127660360921999340
- MahFMilnerMYiuSDonnenfeldEConwayTMHollanderDAPERSIST: Physician’s Evaluation of Restasis® Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewClin Ophthalmol201261971198623226002
- ByunYJKimTIKwonSMEfficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eyeCornea201231550951319730097
- American Academy of Ophthalmology Cornea/External Disease PanelPreferred Practice Pattern®Guidelines. Dry Eye Syndrome – Limited RevisionSan Francisco, CAAmerican Academy of Ophthalmology2011 Available from: http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=127dbdce-4271-471a-b6d9-464b9d15b748Accessed September 14, 2013